Therefore, we reasoned that inducing GITR signaling in Treg cells may be a promising immunotherapeutic strategy to overcome resistance to ICBs in GBM as it would not only reduce suppression of antitumor immunity but also activate potential antitumor effector functions of reprogrammed Treg cells. This evidence concerns the gene TNFRSF18 and glioblastoma.